Grants and Contributions

Scientists and public health authorities worldwide are making an unprecedented collaborative effort to understand and develop effective interventions for the control and prevention of SARS-CoV-2. Vaccination remains the most efficient medical intervention to counteract the pandemic. Viral vaccines have been the most effective in protecting against viral infections. Vectored-vaccine candidates are among the most advanced SARS-CoV-2 in the 38 clinical evaluations (WHO, Draft landscape of COVID-19 candidate vaccines, Sept. 24, 2020). One such platform is using the recombinant Vesicular Stomatitis Virus (rVSV), which is replication competent and is known to induce both cellular and humoral host immune response against foreign antigens. VSV-based vaccine vectors, which, as enveloped viruses, are designed to incorporate glycoprotein antigens into their viral lipid membrane and thus display the antigen on the virus surface, in addition to expressing it upon entry into the target cell. Another important viral vector platform that has been extensively evaluated in preclinical and clinical trials as an onco-therapeutic agent is the Newcastle disease virus (NDV), an avian virus that has several well-suited properties for development of a safe vector vaccine against SARS-CoV-2. Both vectored-vaccine platforms demonstrated good safety profiles and in the case of VSV it has been successfully used for vaccination in emergency situations such as Ebola outbreaks. This Project focus on accelerating vaccine manufacture processes by using a producing cell line compatible with cGMP operations and industrialization to address the challenges posed by large scale manufacturing. The accelerated development the proposed robust technology platform will enable higher and faster accessibility to these class of vectored vaccines in situations of pandemic and contribute to building long lasting capacities in Canada.

Scientists and public health authorities worldwide are making an unprecedented collaborative effort to understand and develop effective interventions for the control and prevention of SARS-CoV-2. Vaccination remains the most efficient medical intervention to counteract the pandemic. Viral vaccines have been the most effective in protecting against viral infections. Vectored-vaccine candidates are among the most advanced SARS-CoV-2 in the 38 clinical evaluations (WHO, Draft landscape of COVID-19 candidate vaccines, Sept. 24, 2020). One such platform is using the recombinant Vesicular Stomatitis Virus (rVSV), which is replication competent and is known to induce both cellular and humoral host immune response against foreign antigens. VSV-based vaccine vectors, which, as enveloped viruses, are designed to incorporate glycoprotein antigens into their viral lipid membrane and thus display the antigen on the virus surface, in addition to expressing it upon entry into the target cell. Another important viral vector platform that has been extensively evaluated in preclinical and clinical trials as an onco-therapeutic agent is the Newcastle disease virus (NDV), an avian virus that has several well-suited properties for development of a safe vector vaccine against SARS-CoV-2. Both vectored-vaccine platforms demonstrated good safety profiles and in the case of VSV it has been successfully used for vaccination in emergency situations such as Ebola outbreaks. This Project focus on accelerating vaccine manufacture processes by using a producing cell line compatible with cGMP operations and industrialization to address the challenges posed by large scale manufacturing. The accelerated development the proposed robust technology platform will enable higher and faster accessibility to these class of vectored vaccines in situations of pandemic and contribute to building long lasting capacities in Canada.

The purpose of this CanExport SMEs agreement is to support small- and medium-sized enterprises (SMEs) for activities related to export market development that are part of an export business case for a specific target market, particularly where activities are targeting departmental priority markets and sectors. 

The purpose of this CanExport SMEs agreement is to support small- and medium-sized enterprises (SMEs) for activities related to export market development that are part of an export business case for a specific target market, particularly where activities are targeting departmental priority markets and sectors. 

The Indigenous Resilience and Adaptability: National Indigenous Courtwork Program Response to COVID-19 project will support a series of interviews and surveys with Indigenous courtworkers, direct program directors, clients, lawyers, provincial/territorial COVID-19 committees for court services, and other relevant stakeholders. This project will examine the impact of the COVID-19 pandemic on the current and future service delivery of Indigenous courtworkers and service users. The project will be national in scope and will look at the following: 1) how each provincial/territorial government is responding to COVID-19 with respect to court services; 2) impact on Indigenous Courtworker programs and their ability to serve Indigenous-accused effectively; 3) identify new challenges and opportunities for Indigenous courtworkers to support the relationships between courts and clients; and 4) identify barriers and solutions to service delivery.

The Indigenous Resilience and Adaptability: National Indigenous Courtwork Program Response to COVID-19 project will support a series of interviews and surveys with Indigenous courtworkers, direct program directors, clients, lawyers, provincial/territorial COVID-19 committees for court services, and other relevant stakeholders. This project will examine the impact of the COVID-19 pandemic on the current and future service delivery of Indigenous courtworkers and service users. The project will be national in scope and will look at the following: 1) how each provincial/territorial government is responding to COVID-19 with respect to court services; 2) impact on Indigenous Courtworker programs and their ability to serve Indigenous-accused effectively; 3) identify new challenges and opportunities for Indigenous courtworkers to support the relationships between courts and clients; and 4) identify barriers and solutions to service delivery.

The purpose of this agreement is to increase awareness, availability and use of lower carbon vehicles and fuels in Canada by supporting the installation of 21 electric vehicle chargers in Ontario.

This project is is to keep spruce budworm (SBW) populations in Atlantic Canada below epidemic levels through targeted insecticide treatments.

The purpose of this agreement is to increase awareness, availability and use of lower carbon vehicles and fuels in Canada by supporting the installation of 21 electric vehicle chargers in Ontario.

Scientists and public health authorities worldwide are making an unprecedented collaborative effort to understand and develop effective interventions for the control and prevention of SARS-CoV-2. Vaccination remains the most efficient medical intervention to counteract the pandemic. Viral vaccines have been the most effective in protecting against viral infections. Vectored-vaccine candidates are among the most advanced SARS-CoV-2 in the 38 clinical evaluations (WHO, Draft landscape of COVID-19 candidate vaccines, Sept. 24, 2020). One such platform is using the recombinant Vesicular Stomatitis Virus (rVSV), which is replication competent and is known to induce both cellular and humoral host immune response against foreign antigens. VSV-based vaccine vectors, which, as enveloped viruses, are designed to incorporate glycoprotein antigens into their viral lipid membrane and thus display the antigen on the virus surface, in addition to expressing it upon entry into the target cell. Another important viral vector platform that has been extensively evaluated in preclinical and clinical trials as an onco-therapeutic agent is the Newcastle disease virus (NDV), an avian virus that has several well-suited properties for development of a safe vector vaccine against SARS-CoV-2. Both vectored-vaccine platforms demonstrated good safety profiles and in the case of VSV it has been successfully used for vaccination in emergency situations such as Ebola outbreaks. This Project focus on accelerating vaccine manufacture processes by using a producing cell line compatible with cGMP operations and industrialization to address the challenges posed by large scale manufacturing. The accelerated development the proposed robust technology platform will enable higher and faster accessibility to these class of vectored vaccines in situations of pandemic and contribute to building long lasting capacities in Canada.